OBJECTIVES: Eosinophilic esophagitis (EoE) is characterized by remissions and relapses. Guidelines defining remission do not exist and therefore remission is inconsistently identified. We sought to define histology remission in EoE. METHODS: Esophageal biopsies, obtained at the time the validated pediatric EoE symptoms scores v2.0 (PEESS v2.0) questionnaire was completed (N = 42), were scored using the validated EoE Histology Scoring System. An EoE Histology Remission Score (EoEHRS) was constructed and specified that in all esophageal sites sampled the peak eosinophil count was <15 per high power field (HPF); in addition, neither the total grade (severity of pathology) nor stage (extent of pathology) scores could exceed 3 (possible total maximum score for each was 24). Spearman correlation coefficients were generated for histology/symptom correlations; coefficient range 0.31 to 0.50 was considered moderate. RESULTS: EoE Histology Scoring System composite and individual feature scores from proximal and distal esophageal biopsies correlated moderately with PEESS v2.0 mean scores (0.48-0.36, P < 0.01), and with scores in the dysphagia (0.39-0.30, P ≤ 0.01), pain (0.48-0.34, P ≤ 0.01), and gastroesophageal reflux disease (0.51-0.32, P ≤ 0.01) domains. Biopsies that met full EoEHRS criteria had reduced biomarkers, specifically expression of the mast cell markers CPA3 and tryptase mRNA, and reduced eosinophil peroxidase deposition (P < 0.03), compared to those with nonremission scores. Subjects whose biopsies met EoEHRS remission criteria reported reduced symptoms for all domains except nausea and vomiting (P ≤ 0.01). CONCLUSIONS: The EoEHRS correlated with reduced biomarkers of disease activity and reduced symptoms, and therefore may be useful to inform clinical care and interstudy comparisons.
OBJECTIVES:Eosinophilic esophagitis (EoE) is characterized by remissions and relapses. Guidelines defining remission do not exist and therefore remission is inconsistently identified. We sought to define histology remission in EoE. METHODS: Esophageal biopsies, obtained at the time the validated pediatric EoEsymptoms scores v2.0 (PEESS v2.0) questionnaire was completed (N = 42), were scored using the validated EoE Histology Scoring System. An EoE Histology Remission Score (EoEHRS) was constructed and specified that in all esophageal sites sampled the peak eosinophil count was <15 per high power field (HPF); in addition, neither the total grade (severity of pathology) nor stage (extent of pathology) scores could exceed 3 (possible total maximum score for each was 24). Spearman correlation coefficients were generated for histology/symptom correlations; coefficient range 0.31 to 0.50 was considered moderate. RESULTS:EoE Histology Scoring System composite and individual feature scores from proximal and distal esophageal biopsies correlated moderately with PEESS v2.0 mean scores (0.48-0.36, P < 0.01), and with scores in the dysphagia (0.39-0.30, P ≤ 0.01), pain (0.48-0.34, P ≤ 0.01), and gastroesophageal reflux disease (0.51-0.32, P ≤ 0.01) domains. Biopsies that met full EoEHRS criteria had reduced biomarkers, specifically expression of the mast cell markers CPA3 and tryptase mRNA, and reduced eosinophil peroxidase deposition (P < 0.03), compared to those with nonremission scores. Subjects whose biopsies met EoEHRS remission criteria reported reduced symptoms for all domains except nausea and vomiting (P ≤ 0.01). CONCLUSIONS: The EoEHRS correlated with reduced biomarkers of disease activity and reduced symptoms, and therefore may be useful to inform clinical care and interstudy comparisons.
Authors: Anjan Dhar; Hasan N Haboubi; Stephen E Attwood; Marcus K H Auth; Jason M Dunn; Rami Sweis; Danielle Morris; Jenny Epstein; Marco R Novelli; Hannah Hunter; Amanda Cordell; Sharon Hall; Jamal O Hayat; Kapil Kapur; Andrew Robert Moore; Carol Read; Sarmed S Sami; Paul J Turner; Nigel J Trudgill Journal: Gut Date: 2022-05-23 Impact factor: 31.793
Authors: Evan S Dellon; Paneez Khoury; Amanda B Muir; Chris A Liacouras; Ekaterina Safroneeva; Dan Atkins; Margaret H Collins; Nirmala Gonsalves; Gary W Falk; Jonathan M Spergel; Ikuo Hirano; Mirna Chehade; Alain M Schoepfer; Calies Menard-Katcher; David A Katzka; Peter A Bonis; Albert J Bredenoord; Bob Geng; Elizabeth T Jensen; Robert D Pesek; Paul Feuerstadt; Sandeep K Gupta; Alfredo J Lucendo; Robert M Genta; Girish Hiremath; Emily C McGowan; Fouad J Moawad; Kathryn A Peterson; Marc E Rothenberg; Alex Straumann; Glenn T Furuta; Seema S Aceves Journal: J Allergy Clin Immunol Date: 2022-05-20 Impact factor: 14.290
Authors: Evan S Dellon; Paneez Khoury; Amanda B Muir; Chris A Liacouras; Ekaterina Safroneeva; Dan Atkins; Margaret H Collins; Nirmala Gonsalves; Gary W Falk; Jonathan M Spergel; Ikuo Hirano; Mirna Chehade; Alain M Schoepfer; Calies Menard-Katcher; David A Katzka; Peter A Bonis; Albert J Bredenoord; Bob Geng; Elizabeth T Jensen; Robert D Pesek; Paul Feuerstadt; Sandeep K Gupta; Alfredo J Lucendo; Robert M Genta; Girish Hiremath; Emily C McGowan; Fouad J Moawad; Kathryn A Peterson; Marc E Rothenberg; Alex Straumann; Glenn T Furuta; Seema S Aceves Journal: Gastroenterology Date: 2022-05-20 Impact factor: 33.883
Authors: Ikuo Hirano; Margaret H Collins; Eileen King; Qin Sun; Mirna Chehade; J Pablo Abonia; Peter A Bonis; Kelly E Capocelli; Evan S Dellon; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; John Leung; David Katzka; Paul Menard-Katcher; Paneez Khoury; Amy Klion; Vincent A Mukkada; Kathryn Peterson; Tetsuo Shoda; Amanda K Rudman-Spergel; Jonathan A Spergel; Guang-Yu Yang; Marc E Rothenberg; Seema S Aceves; Glenn T Furuta Journal: Am J Gastroenterol Date: 2022-03-01 Impact factor: 12.045
Authors: Dmitri Atiakshin; Andrey Kostin; Ivan Trotsenko; Vera Samoilova; Igor Buchwalow; Markus Tiemann Journal: Cells Date: 2022-02-06 Impact factor: 6.600